Acadian Asset Management LLC trimmed its position in shares of Surmodics, Inc. (NASDAQ:SRDX – Free Report) by 1.5% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 402,660 shares of the company’s stock after selling 6,119 shares during the quarter. Acadian Asset Management LLC’s holdings in Surmodics were worth $16,923,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of SRDX. Panagora Asset Management Inc. raised its stake in shares of Surmodics by 109.8% during the fourth quarter. Panagora Asset Management Inc. now owns 44,664 shares of the company’s stock worth $1,624,000 after acquiring an additional 23,379 shares in the last quarter. Bailard Inc. purchased a new position in Surmodics in the 2nd quarter worth $257,000. Nisa Investment Advisors LLC lifted its stake in Surmodics by 4,722.3% in the second quarter. Nisa Investment Advisors LLC now owns 68,429 shares of the company’s stock worth $2,877,000 after purchasing an additional 67,010 shares during the last quarter. Hillsdale Investment Management Inc. boosted its position in Surmodics by 15.7% during the fourth quarter. Hillsdale Investment Management Inc. now owns 4,570 shares of the company’s stock valued at $166,000 after buying an additional 620 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Surmodics by 0.7% during the first quarter. Vanguard Group Inc. now owns 865,214 shares of the company’s stock valued at $25,385,000 after buying an additional 5,927 shares during the last quarter. Institutional investors own 96.63% of the company’s stock.
Surmodics Trading Up 1.3 %
SRDX opened at $39.32 on Tuesday. Surmodics, Inc. has a one year low of $25.17 and a one year high of $42.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.22. The business has a 50 day simple moving average of $40.83 and a two-hundred day simple moving average of $35.81. The firm has a market capitalization of $561.10 million, a price-to-earnings ratio of 41.39 and a beta of 1.20.
Analysts Set New Price Targets
Get Our Latest Research Report on Surmodics
Surmodics Profile
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Read More
- Five stocks we like better than Surmodics
- What is a buyback in stocks? A comprehensive guide for investors
- Why Block’s Key Components Make It a Solid Investment Choice
- What Does Downgrade Mean in Investing?
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- Investing in Commodities: What Are They? How to Invest in Them
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Want to see what other hedge funds are holding SRDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surmodics, Inc. (NASDAQ:SRDX – Free Report).
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.